Cargando…

Development of CAR T Cell Therapy in Children—A Comprehensive Overview

CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boettcher, Michael, Joechner, Alexander, Li, Ziduo, Yang, Sile Fiona, Schlegel, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024694/ https://www.ncbi.nlm.nih.gov/pubmed/35456250 http://dx.doi.org/10.3390/jcm11082158

Ejemplares similares

CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
por: Bębnowska, Dominika, et al.
Publicado: (2020)

The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
por: Schaft, Niels
Publicado: (2020)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

CAR T-Cell Therapy in Children with Solid Tumors
por: Kulczycka, Marika, et al.
Publicado: (2023)

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
por: Xu, Xinjie, et al.
Publicado: (2021)

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
por: Atar, Daniel, et al.
Publicado: (2022)

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
por: Awasthi, Rakesh, et al.
Publicado: (2023)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review
por: Kim, Tae Jin, et al.
Publicado: (2022)

Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses
por: Zarezadeh Mehrabadi, Ali, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy
por: Pagotto, Sara, et al.
Publicado: (2023)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Donor T cells for CAR T cell therapy
por: Tang, Tiffany C. Y., et al.
Publicado: (2022)

Clinical development of CAR T cell therapy in China: 2020 update
por: Wei, Jianshu, et al.
Publicado: (2020)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
por: Herrera, Lara, et al.
Publicado: (2021)

Global Manufacturing of CAR T Cell Therapy
por: Levine, Bruce L., et al.
Publicado: (2016)

CAR T-Cell Therapy in Hematological Malignancies
por: Haslauer, Theresa, et al.
Publicado: (2021)

CAR-T Cell Therapy and the Gut Microbiota
por: Asokan, Sahana, et al.
Publicado: (2023)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas
por: Ahmad, Aamir, et al.
Publicado: (2020)

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
por: Mc Laughlin, Anna M., et al.
Publicado: (2023)

An overview of CAR T-cell clinical trial activity to 2021
por: Adami, Antonella, et al.
Publicado: (2021)

A Comprehensive Overview of the Developments of Cdc25 Phosphatase Inhibitors
por: Abdelwahab, Ahmed Bakr, et al.
Publicado: (2022)

CAR-T Cell Therapy: From the Shop to Cancer Therapy
por: Uscanga-Palomeque, Ashanti Concepción, et al.
Publicado: (2023)

Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies
por: Mhaidly, Rana, et al.
Publicado: (2020)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

CAR‐T cell therapy for lung cancer: Potential and perspective
por: Chen, Long, et al.
Publicado: (2022)

Toxicity and management in CAR T-cell therapy
por: Bonifant, Challice L, et al.
Publicado: (2016)

Practical issues in CAR T-cell therapy
por: Byun, Ja Min
Publicado: (2023)

Outcomes of CAR-T Cell Therapy Recipients Admitted to the ICU: In Search for a Standard of Care—A Brief Overview and Meta-Analysis of Proportions
por: Constantinescu, Catalin, et al.
Publicado: (2023)

The expansion of targetable biomarkers for CAR T cell therapy
por: Townsend, Michelle H., et al.
Publicado: (2018)

CAR T-Cell Therapy: Adverse Events and Management
por: Adkins, Sherry
Publicado: (2019)

Podoplanin as an Attractive Target of CAR T Cell Therapy
por: Waseda, Masazumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_743e1dj9mthqk5l9g1ks5fdl5h